Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19

Raaka Kumbhakar,Moni Neradilek,Ruanne Barnabas,Jenell Stewart,Helen C. Stankiewicz Karita,Raphael J. Landovitz,Patricia J. Kissinger,Keith R. Jerome,Michael K. Paasche-Orlow,Anna Bershteyn,Helen Y. Chu,Kathleen M. Neuzil,Alexander L. Greninger,Alfred Luk,Anna Wald,Elizabeth R. Brown,Christine Johnston

JOURNAL OF MEDICAL VIROLOGY（2022）

Cited 0|Views19

No score

Abstract

Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either postexposure prophylaxis or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated the time-weighted average change from baseline SARS-CoV-2 viral load and demonstrated that HCQ did not affect viral clearance.

Translated text

Key words

COVID-19,early treatment,hydroxychloroquine,PEP,SARS-CoV-2

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined